Company Intelligence
Amgen is one of the world's largest biotechnology companies, pioneering treatments in oncology, cardiovascular disease, bone health, neuroscience, and inflammation. The company's portfolio includes blockbuster drugs like Enbrel, Prolia, Repatha, and Lumakras. Amgen's $28.3 billion acquisition of Horizon Therapeutics in 2023 significantly expanded its rare disease portfolio, and the company is investing heavily in its obesity drug pipeline to compete in one of the fastest-growing therapeutic areas.
Pharmaceuticals & Life Sciences
Headquarters
Thousand Oaks, CA
Employees
~27,000
Revenue
$33.4B (FY2024)
Fiscal Year End
December 31
Founded
1980
Current leadership team based on public filings and announcements.
Robert Bradway
Chairman & CEO
Peter Griffith
EVP & CFO
Key events and changes that sales teams should know about.
Completed the integration of Horizon Therapeutics ($28.3B acquisition), adding rare disease treatments including Tepezza and Krystexxa to Amgen's portfolio and expanding into specialty therapeutics.
2024-12
Advanced its obesity drug pipeline with MariTide (AMG 133), a GIP receptor antagonist/GLP-1 agonist showing promising weight loss data in clinical trials, positioning Amgen to compete with Novo Nordisk and Eli Lilly.
2024-10
Q2 2024 revenue reached $8.4B, up 20% YoY largely driven by the Horizon Therapeutics portfolio and continued growth of Repatha and biosimilar products.
2024-08
Expanded biosimilar portfolio with new launches targeting major reference biologics, leveraging Amgen's manufacturing expertise to capture share in the growing biosimilar market.
2024-06
Invested in next-generation biomanufacturing facilities and AI-driven drug discovery capabilities, modernizing its R&D and production infrastructure for the next decade of growth.
2024-04
Amgen is one of the largest technology buyers in the biotechnology space. With ~27,000 employees, a global commercial operation, and complex R&D workflows, the company spends heavily on cloud infrastructure, data analytics, laboratory information systems, CRM (likely Veeva), and enterprise software. Vendors selling into pharma/biotech should understand that Amgen's size means long procurement cycles, rigorous vendor qualification processes, and a preference for validated, GxP-compliant solutions.
The Horizon Therapeutics acquisition creates significant integration-related technology spending. Merging two large organizations requires IT infrastructure consolidation, data migration, systems integration, and change management. Vendors specializing in M&A integration services, data harmonization, or enterprise platform consolidation will find opportunities in the 18-24 months following the close of a deal this size.
Amgen's push into obesity therapeutics and AI-driven drug discovery signals a modernization of its R&D technology stack. The company is investing in computational biology, machine learning for clinical trial design, and real-world evidence platforms. Vendors in the AI/ML, cloud compute, and life sciences data spaces should monitor Amgen's R&D technology procurement as the company builds out these capabilities to compete with Novo Nordisk and Eli Lilly in obesity.
Key competitors based on market analysis and public filings.
Amgen's fiscal year ends on December 31, following the standard calendar year. Q4 earnings are typically reported in late January or early February, and the December quarter is important for year-end procurement and budget decisions.
Amgen generated approximately $33.4 billion in revenue for fiscal year 2024, a significant increase driven largely by the inclusion of Horizon Therapeutics products. The company's core portfolio includes blockbusters like Prolia, Repatha, EVENITY, and the newly acquired Tepezza.
Amgen completed its $28.3 billion acquisition of Horizon Therapeutics in October 2023. The deal added rare disease treatments including Tepezza (thyroid eye disease) and Krystexxa (chronic gout) to Amgen's portfolio, representing the company's largest-ever acquisition and a strategic expansion into rare and specialty diseases.
Yes. Amgen is developing MariTide (AMG 133), a novel obesity drug that combines GIP receptor antagonism with GLP-1 receptor agonism. Early clinical data showed significant weight loss, and the company is advancing the program through clinical trials to compete in the obesity market alongside Novo Nordisk (Wegovy) and Eli Lilly (Zepbound).
Amgen employs approximately 27,000 people globally, including a significant increase from the Horizon Therapeutics acquisition. The company has major operations in Thousand Oaks (CA), Cambridge (MA), and manufacturing sites across the US and internationally.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Amgen — updated continuously.
